Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.11M | -21.24M | -20.16M | -19.39M | -18.59M |
| Total Depreciation and Amortization | 49.50K | 44.60K | 45.00K | 39.10K | 37.90K |
| Total Amortization of Deferred Charges | 50.00K | 50.00K | 49.00K | 48.00K | 48.00K |
| Total Other Non-Cash Items | 2.18M | 2.71M | 2.61M | 3.11M | 2.95M |
| Change in Net Operating Assets | -1.13M | -939.30K | -1.01M | -1.11M | -2.90M |
| Cash from Operations | -18.95M | -19.37M | -18.47M | -17.30M | -18.45M |
| Capital Expenditure | -- | -- | -- | -900.00 | -900.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -42.50K | -42.50K |
| Cash from Investing | -- | -- | -- | -43.40K | -43.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.80K | -99.70K | -96.40K | -94.20K | -92.30K |
| Issuance of Common Stock | 25.85M | 26.95M | 28.94M | 14.70M | 8.08M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -395.50K | -395.50K | -395.50K | -395.50K | 0.00 |
| Cash from Financing | 25.35M | 26.46M | 28.45M | 14.21M | 7.99M |
| Foreign Exchange rate Adjustments | -12.50K | 389.20K | 474.10K | -104.30K | 271.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.39M | 7.47M | 10.46M | -3.24M | -10.24M |